251548-94-4

Basic information

• Product Name: Benzenamine, 2-iodo-4-(methylsulfonyl)-
• CAS NO: 251548-94-4
• Molecular Formula: C7H8INO2S
• Molecular Weight: 297.117
• Mol File: 251548-94-4.mol

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2-iodo-4-(methylsulfonyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2-iodo-4-(methylsulfonyl)-(251548-94-4)
• EPA Substance Registry System: Benzenamine, 2-iodo-4-(methylsulfonyl)-(251548-94-4)

Safety Data

• Hazardous Substances Data: 251548-94-4(Hazardous Substances Data)

Upstream product

• 104-96-1 4-methylsulfanylaniline 
• 251548-93-3 2,2-dimethyl-N-(2-iodo-4-methanesulfonylphenyl)propionamide 
• 5470-49-5 4-methanesulfonylphenylamine 
• 177662-76-9 (4-methylsulfonyl)aniline hydrochloride 

Downstream Products

• 251548-95-5 1-Bisbenzenesulfonylamino-2-iodo-4-methanesulfonylbenzene 
• 280772-88-5 2-[(4-boc-Piperazin-1-ylcarbonyl)amino]-5-(methylsulfonyl)iodobenzene 
• 280772-78-3 2-[(1-boc-Piperidin-4-ylcarbonyl)amino]-5-methylsulfonyliodobenzene 
• 795281-21-9 [5-acetyl-4-(4-chloro-benzyl)-7-methanesulfonyl-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid 
• 393508-94-6 [5-acetyl-4-(4-chlorobenzyl)-7-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid 
• 393509-13-2 methyl [5-acetyl-4-(4-chlorobenzyl)-7-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetate 
• 393509-12-1 methyl [5-bromo-4-(4-chlorobenzyl)-7-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetate 

Relevant articles and documents

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524)

The discovery of the potent and selective prostaglandin D2 (PGD2) receptor (DP) antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5- (methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (13) is presented. Initial lead antagonists 6 and 7 were found to be potent and selective DP antagonists (DP Ki = 2.0 nM for each); however, they both suffered from poor pharmacokinetic profiles, short half-lives and high clearance rates in rats. Rat bile duct cannulation studies revealed that high concentrations of parent drug were present in the biliary fluid (Cmax = 1100 μM for 6 and 3900 μM for 7). This pharmacokinetic liability was circumvented by replacing the 7-methylsulfone substituent present in 6 and 7 with a fluorine atom resulting in antagonists with diminished propensity for biliary excretion and with superior pharmacokinetic profiles. Further optimization led to the discovery of the potent and selective DP antagonist 13.

Methanesulfonyl-polarized halogen bonding enables strong halide recognition in an arylethynyl anion receptor

A 3,5-bis((2-iodophenyl)ethynyl)pyridinium scaffold was synthesized which introduces the use of methanesulfonyl withdrawing groups to polarize iodine halogen bonding units for anion binding. We investigate the capability of this receptor to bind halides in polar media, while further probing the structure-property relationship of this well-polarized yet under-explored halogen bonding system.

THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Identification of an indole series of prostaglandin D2 receptor antagonists

A novel indole series of PGD2 receptor (DP receptor) antagonists is presented. Optimization of this series led to the identification of potent and selective DP receptor antagonists. In particular, antagonists 35 and 36 were identified with Ksu

Heterocyclic indole derivatives and mono- or diazaindole derivatives

There is provided a compound represented by the general formula (1): wherein Het represents an optionally substituted heterocyclic group; A1and A2each independently represent —CH═, etc.; A3represents —CH2—, etc.; R1represents a 4-fluorophenyl group, etc.; R2represents an alkyl group; n represents 0, 1 or 2, provided that when A1and A2both are —CH═, A3represents —CH2— or —SO2—, which is an indole derivative or a mono- or diazaindole derivative that has COX-2 inhibitory activity and is useful as a pharmaceutical, such as an anti-inflammatory agent, or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.

Efficient synthesis of bromocyclopenta[b]indoles via a bromination - Reduction sequence

Substituted cyclopenta[b]indoles are selectively brominated in good yields with excess pyridine - Br2 charge-transfer complex (PyBr2) in a one-pot reaction to provide 5 and/or 7-bromoindoles. The mechanism involves the formation of a

AROMATIC AMIDES

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Substituted cyclopentanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.